
Goldshield appoints John Beighton
pharmafile | July 15, 2010 | Appointment | Sales and Marketing |Â Â Goldshield, appointment, sales and marketingÂ
UK generics company Goldshield has appointed John Beighton as chief executive.
Beighton was formerly UK managing director of Teva, and begun his pharma career with SmithKline Beecham as a medical rep.
He will be joined by new chairman Richard Connell, who has a 30-year background in the private equity business and most-recently headed up UK operations of Invesco.
Goldshield’s former chief executive Rakesh Patel and founder and former group executive director Kirti Patel have both stepped down from active management of the company but remain significant shareholders and advisors.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






